Test Catalog

Test ID: NGSHM    
OncoHeme Next-Generation Sequencing for Myeloid Neoplasms

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation of hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm) at the time of diagnosis or possibly disease relapse, to help determine diagnostic classification and provide prognostic or therapeutic information for clinical management

 

Determine the presence of new clinically important gene mutation changes at relapse

Genetics Test Information Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test includes next-generation sequencing to evaluate for the following 42 genes and select intronic regions: ANKRD26, ASXL1, BCOR, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A,ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SRP72, SMC3, SRSF2, STAG2,TERT, TET2, TP53, U2AF1, WT1, and ZRSR2.

Highlights

Next-generation sequencing detection of somatic gene mutations, including type, pattern and distribution, has diagnostic, prognostic, and potential therapeutic implications for patients with hematologic cancers of myeloid origin.

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

The following are available in Special Instructions:

-Targeted Genes Interrogated by OncoHeme Next-Generation Sequencing; this is a list of the genes and exons targeted by this test.

-Myelodysplastic Syndrome: Guideline to Diagnosis and Follow-up

-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Somatic Mutation Detection by Next-Generation Sequencing (NGS)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

NGS for Myeloid Neoplasms (NGSHM)

Aliases Lists additional common names for a test, as an aid in searching

NGS hematologic malignancies
NGS cancer panel, hematologic
Somatic mutation detection by next generation sequencing (NGS), hematologic
Next gen sequencing of leukemia (AML) and myelodysplasia (MDS)
NGS for myeloid neoplasm evaluation (MPN)
Next Gen Sequencing Test
ASXL1
BCOR
CALR
CBL
CEBPA
CSF3R
DNMT3A
ETV6
EZH2
FLT3
GATA1
GATA2
IDH1
IDH2
JAK2
KIT
KRAS
MPL
NPM1
NRAS
PHF6
PTPN11
RUNX1
SETBP1
SF3B1
SRSF2
TERT
TET2
TP53
U2AF1
WT1
ZRSR2
ANKRD26
DDX41
ELANE
ETNK1
KDM6A
RAD21
SH2B3
SRP72
SMC3
STAG2